Hutchison China MediTech Limited (HCM.L)
| Previous close | 542.00 |
| Open | 553.97 |
| Bid | 554.00 x 0 |
| Ask | 557.00 x 0 |
| Day's range | 549.30 - 559.00 |
| 52-week range | 337.00 - 656.00 |
| Volume | 209,095 |
| Avg. volume | 243,524 |
| Market cap | 4.806B |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -18.00 |
| Earnings date | 28 Jul 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 65.02 |
- Globe Newswire
HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma
HONG KONG and SHANGHAI, China and FLORHAM PARK, N,J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to amdizalisib (HMPL-689), a highly selective and potent PI3Kδ inhibitor, for the treatment of relapsed or refractory follicular lymphoma (“FL”), a subtype of non-Hodgkin’s lympho
- Globe Newswire
HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
— Follows important findings from the SAVANNAH study of this combination in lung cancer patients whose tumors harbor mutations or aberrations of EGFR and MET —HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq:AZN) have initiated SANOVO, a China Phase III study of ORPATHYS® (savolitinib), an oral, potent, and highly selective MET tyrosine kinase i
- Globe Newswire
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new analyses and updates on the ongoing studies of amdizalisib (PI3Kδ inhibitor HMPL-689), savolitinib (ORPATHYS® in China) and fruquintinib (ELUNATE® in China) will be presented at the upcoming 2021 European Society for Medical Oncology (“ESMO”) Virtual Congress taking place on September 16-21, 2021. AMDIZALISIB (also known
